Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL677926 | 0.73 | SLC6A9 (0.62) | SLC6A9 | |
| SCHEMBL3693197 | 0.72 | SLC6A9 (0.66) | SLC6A9 | |
| SCHEMBL679425 | 0.71 | SLC6A9 (0.65) | SLC6A9LMNA | |
| SCHEMBL3379442 | 0.71 | SLC6A9 (0.46) | SLC6A9TSHRL3MBTL1GAALMNA | |
| SCHEMBL3379441 | 0.71 | SLC6A9 (1.00) | SLC6A9 | |
| SCHEMBL678833 | 0.71 | SLC6A9 (0.69) | SLC6A9 | |
| SCHEMBL678835 | 0.71 | SLC6A9 (0.64) | SLC6A9 | |
| SCHEMBL679655 | 0.70 | SLC6A9 (0.63) | SLC6A9LMNA | |
| SCHEMBL679912 | 0.69 | SLC6A9 (0.65) | SLC6A9PKMCYP2C19 | |
| SCHEMBL4003614 | 0.69 | SLC6A9 (0.61) | SLC6A9GAASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269782-A1 | USE OF NMDA ACTIVITY ENHANCERS TO TREAT HYPERSOMNIA, REDUCED WAKEFULNESS OR REDUCED VIGILANCE | MERCK, SHARP & DOHME LTD. (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | SLC1A2, SLC1A1, SLC1A3 | SLC6A9 31/4885TSHR 3329/4885L3MBTL1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.